A Safety Study Of The Caya® Diaphragm Used With ContraGel®

Contraception Clinical Trial

Official title: A Phase I Safety Study Of The Caya® Diaphragm Used With ContraGel®

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety of ContraGel versus the hydroxyethylcellulose (HEC) Universal Placebo gel when used with the Caya diaphragm during two 7-day periods of daily use, the first without intercourse and the second with intercourse.

Clinical Trial Description

This single-center randomized, parallel, Phase I study will compare the safety of ContraGel delivered by the Caya diaphragm versus HEC universal placebo gel delivered by the Caya diaphragm in approximately 24 healthy premenopausal women protected from pregnancy by female sterilization. Women will use the assigned product during two 7-day periods of daily use, the first without intercourse and the second with intercourse.

Each woman will be seen in approximately 6 visits and will be contacted via one scheduled follow-up call after Visit 6.

At Visit 1, volunteers will be consented and undergo procedures to confirm they are eligible to continue in the study.

At Visit 2, once it has been confirmed that the participant meets all of the inclusion criteria and none of the exclusion criteria, baseline genital tract samples will be taken.

At Visit 3,baseline genital tract samples will be taken for Test Cycle 1 (before product use with no intercourse). Participants will be randomized in a 1:1 ratio to insert the Caya diaphragm to deliver either ContraGel or the HEC placebo every day for two 7-day periods in two separate menstrual cycles. The participant will receive study supplies. She will be instructed to refrain from intercourse during the first 7-day period and to insert the Caya each day for between 6-12 hours. She will be instructed to return to the clinic at Visit 4 with the diaphragm in place.

At Visit 4, genital tract samples will be taken after 7 days of product use without intercourse (Test Cycle 1).

At Visit 5, baseline genital tract samples will be taken for Test Cycle 2 (before product use with intercourse). The participant will receive study supplies and will be instructed to engage in two sex acts during this 7-day period, the second sex act to take place using the study products 6-12 hours prior to Visit 6. Participants will be instructed to return to the clinic at Visit 6 with the diaphragm still in place.

At Visit 6, genital tract samples will be taken after 7 days of product use with intercourse (Test Cycle 2).

A follow-up call/contact will be scheduled for 1 to 2 weeks after Visit 6. The participant will be asked about any adverse events (AEs) experienced and medications taken since the last visit. The participant will then be exited from the study, unless she has symptoms that require follow-up. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Contraception

• NCT number: NCT02462954
• Study type: Interventional
• Source: CONRAD
• Status: Completed
• Phase: Phase 1
• Start date: July 2015
• Completion date: April 2016